Tags

Type your tag names separated by a space and hit enter

Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
Int Urol Nephrol. 2018 Oct; 50(10):1863-1870.IU

Abstract

PURPOSE

The complexity of chronic kidney disease-mineral and bone disorder (CKD-MBD) led to many preclinical and clinical trials. The role of sclerostin in renal pathophysiology remained unresolved, and question whether sclerostin is related to cardiovascular (CV) outcome in patients with CKD is still open. Our aim was to evaluate the possible association between serum sclerostin levels and carotid intima-media thickness (CIMT) in CV pathophysiology through various CKD stages.

METHODS

Eighty-eight patients in various CKD stages were involved in this analysis. CKD-EPI (Chronic kidney disease Epidemiology Collaboration Equation) was used to estimate glomerular filtration rate (eGFR). CKD-MBD parameters were determined in patients' serum after an overnight fasting. Early atherosclerosis was assessed by ultrasound measurement of CIMT. In order to assess the association between serum sclerostin with other CKD-MBD parameters and CIMT, correlation and regression analyses were performed.

RESULTS

Mean age was 62.84 ± 11.37 years and 56% were female. Mean values of serum sclerostin were 1.67 ± 0.44 ng/ml. Negative correlation was noticed with serum calcium and phosphate product (CaxP), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), serum creatinine, and HbA1c level. There was no association with FGF23, CIMT, and carotid atherosclerotic plaque occurence. Serum levels of sclerostin were significantly higher in female patients compared to males (p < 0.001).

CONCLUSION

Advanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD-MBD pathophysiological mechanism.

Authors+Show Affiliations

Department of Nephrology, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina. andrejafigurek@yahoo.com. Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina. andrejafigurek@yahoo.com.University Department of Nephrology, Medical Faculty, University of Skopje, Skopje, Macedonia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30030677

Citation

Figurek, Andreja, and Goce Spasovski. "Is Serum Sclerostin a Marker of Atherosclerosis in Patients With Chronic Kidney Disease-mineral and Bone Disorder?" International Urology and Nephrology, vol. 50, no. 10, 2018, pp. 1863-1870.
Figurek A, Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol. 2018;50(10):1863-1870.
Figurek, A., & Spasovski, G. (2018). Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? International Urology and Nephrology, 50(10), 1863-1870. https://doi.org/10.1007/s11255-018-1935-5
Figurek A, Spasovski G. Is Serum Sclerostin a Marker of Atherosclerosis in Patients With Chronic Kidney Disease-mineral and Bone Disorder. Int Urol Nephrol. 2018;50(10):1863-1870. PubMed PMID: 30030677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? AU - Figurek,Andreja, AU - Spasovski,Goce, Y1 - 2018/07/20/ PY - 2018/04/09/received PY - 2018/07/06/accepted PY - 2018/7/22/pubmed PY - 2019/1/27/medline PY - 2018/7/22/entrez KW - Biomarker KW - Chronic kidney disease KW - Intima-media thickness KW - Mineral and bone disorder KW - Sclerostin SP - 1863 EP - 1870 JF - International urology and nephrology JO - Int Urol Nephrol VL - 50 IS - 10 N2 - PURPOSE: The complexity of chronic kidney disease-mineral and bone disorder (CKD-MBD) led to many preclinical and clinical trials. The role of sclerostin in renal pathophysiology remained unresolved, and question whether sclerostin is related to cardiovascular (CV) outcome in patients with CKD is still open. Our aim was to evaluate the possible association between serum sclerostin levels and carotid intima-media thickness (CIMT) in CV pathophysiology through various CKD stages. METHODS: Eighty-eight patients in various CKD stages were involved in this analysis. CKD-EPI (Chronic kidney disease Epidemiology Collaboration Equation) was used to estimate glomerular filtration rate (eGFR). CKD-MBD parameters were determined in patients' serum after an overnight fasting. Early atherosclerosis was assessed by ultrasound measurement of CIMT. In order to assess the association between serum sclerostin with other CKD-MBD parameters and CIMT, correlation and regression analyses were performed. RESULTS: Mean age was 62.84 ± 11.37 years and 56% were female. Mean values of serum sclerostin were 1.67 ± 0.44 ng/ml. Negative correlation was noticed with serum calcium and phosphate product (CaxP), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), serum creatinine, and HbA1c level. There was no association with FGF23, CIMT, and carotid atherosclerotic plaque occurence. Serum levels of sclerostin were significantly higher in female patients compared to males (p < 0.001). CONCLUSION: Advanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD-MBD pathophysiological mechanism. SN - 1573-2584 UR - https://www.unboundmedicine.com/medline/citation/30030677/Is_serum_sclerostin_a_marker_of_atherosclerosis_in_patients_with_chronic_kidney_disease_mineral_and_bone_disorder L2 - https://doi.org/10.1007/s11255-018-1935-5 DB - PRIME DP - Unbound Medicine ER -